Abemaciclib
Abemaciclib is a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, a class of targeted cancer therapeutics indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2, also called ERBB2)-negative (HR+/HER2−) breast cancer.
Abemaciclib is a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, a class of targeted cancer therapeutics indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2, also called ERBB2)-negative (HR+/HER2−) breast cancer. The drug represents a crucial first-line treatment component for advanced and metastatic breast cancer, where it is considered an essential part of standard-of-care management. By inhibiting CDK4/6-mediated cell cycle progression, abemaciclib prevents cancer cells from transitioning through the G1/S checkpoint, thereby suppressing tumor cell proliferation. The drug's mechanism is particularly effective when combined with endocrine therapy agents in hormone receptor-positive disease, reflecting the synergistic targeting of both growth signaling pathways and hormone receptor function. Recent evidence suggests potential utility beyond breast cancer, with CDK4/6 inhibitors including abemaciclib being investigated for application in other malignancies such as meningioma.
Where the papers sit
11 papers from the last 6 months study abemaciclib directly · updated from PubMed 16 Nov 2026
Study type 2 clinical trials · 5 observational · 4 preclinical
Themes 3 themes · 1 new direction
-
Breast Cancer Treatment and Toxicity
Hormone receptor-positive, HER2-negative breast cancer care is moving toward sustained abemaciclib use with endocrine therapy, while tolerability and adherence constrain treatment. Rechallenge after progression and outcomes across palbociclib, ribociclib and abemaciclib remain clinically relevant, especially in older patients with comorbidities. Recurring toxicities include diarrhea, neutropenic enterocolitis and serious drug-induced liver injury, with rare retinal artery occlusion also reported. Adjuvant benefit must therefore be balanced against monitoring, patient experience and treatment persistence.
7 papers · 63.6%
-
Overcoming Therapy Resistance
Abemaciclib is being tested as a way to counter therapy resistance driven by EGFR C797S and treatment-associated lineage plasticity. In EGFR-mutant lung adenocarcinoma, combination with osimertinib is aimed at restoring control after resistance, with patient-derived xenografts supporting the approach. In diffuse midline glioma, CDK4/6 inhibition is combined with temozolomide and radiation to address adaptive state changes. The evidence remains preclinical, and the shared question is whether cell-cycle blockade can delay or reverse resistant disease.
2 papers · 18.2%
-
Others — Preclinical Drug Assessment
Drug evaluation spans gut-liver microphysiological models and validated chromatographic measurement of abemaciclib with olaparib. The gut-liver platform adds immune and metabolic functions to toxicity and pharmacology testing. The analytical work emphasizes stability, selectivity and precise quantification. These papers share an assessment focus but do not establish a common biological disease or therapeutic direction.
2 papers · 18.2%
Abemaciclib is repurposed as a direct inhibitor of osimertinib-resistant mutant EGFR
The EGFR-mutant lung adenocarcinoma study used C797S-containing EGFR triple-mutant Ba/F3 cells, isogenic models, xenografts, and patient-derived xenografts to show that abemaciclib preferentially suppresses mutant-EGFR-dependent growth and can overcome osimertinib resistance 43021317Nov. This departs from the set’s breast-cancer-centered use of abemaciclib as a CDK4/6 inhibitor: the drug is assigned a distinct role as an inhibitor of oncogenic EGFR signaling, creating a potential treatment strategy for a resistance state with limited options.
Papers
The 11 papers from the last 6 months that study abemaciclib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Breast Cancer Treatment and Toxicity (7)
- Fatal drug-induced liver injury in the setting of abemaciclib therapy for metastatic breast cancer. BMJ case reports · 5 Oct 2026 PMID 42833841
- Abemaciclib and lenalidomide presenting with central retinal artery occlusion in a patient with breast cancer and multiple myeloma: a possible treatment-related association. BMJ case reports · 28 Sept 2026 PMID 42805625
- Tolerability and adherence to adjuvant abemaciclib in hormone receptor-positive, HER2-negative, node-positive high-risk early breast cancer: a real-world study. Acta oncologica (Stockholm, Sweden) · 2 Sept 2026 PMID 42684120
- Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B). Breast cancer research and treatment · 20 Jul 2026 PMID 42474572
- A Case of Neutropenic Enterocolitis During Endocrine Therapy With Abemaciclib for Metastatic Breast Cancer. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379793
- Age, Age-Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation-Wide Retrospective Cohort Study. Pharmacoepidemiology and drug safety · 16 Jun 2026 PMID 42301003
- Perceptions and lived experiences with abemaciclib and endocrine therapy for early breast cancer: a rapid communication. Future oncology (London, England) · 22 May 2026 PMID 42169666
Overcoming Therapy Resistance (2)
- Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma. Journal of biomedical science · 12 Nov 2026 PMID 43021317
- Therapy-associated lineage plasticity in DIPG following combined CDK4/6 inhibitor, temozolomide, and radiation. Cancer letters · 30 Jul 2026 PMID 42532370
Others — Preclinical Drug Assessment (2)
- Integrated "gut-liver"-on-a-chip (iGLoC): an immune-competent and metabolically active microphysiological model of the gut-liver axis for drug screening, validated by abemaciclib pharmacokinetics, hepatotoxicity, and drug-drug interaction studies. Lab on a chip · 6 Aug 2026 PMID 42557890
- Development of a stability-indicating RP-UPLC method for simultaneous determination of Abemaciclib and Olaparib with LC-MS characterization of degradation products and in vitro performance evaluation. Journal of chromatographic science · 23 Jul 2026 PMID 42490602
By study type
Clinical trials (2)
- Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B). Breast cancer research and treatment · 20 Jul 2026 PMID 42474572
- Perceptions and lived experiences with abemaciclib and endocrine therapy for early breast cancer: a rapid communication. Future oncology (London, England) · 22 May 2026 PMID 42169666
Observational studies and case reports (5)
- Fatal drug-induced liver injury in the setting of abemaciclib therapy for metastatic breast cancer. BMJ case reports · 5 Oct 2026 PMID 42833841
- Abemaciclib and lenalidomide presenting with central retinal artery occlusion in a patient with breast cancer and multiple myeloma: a possible treatment-related association. BMJ case reports · 28 Sept 2026 PMID 42805625
- Tolerability and adherence to adjuvant abemaciclib in hormone receptor-positive, HER2-negative, node-positive high-risk early breast cancer: a real-world study. Acta oncologica (Stockholm, Sweden) · 2 Sept 2026 PMID 42684120
- A Case of Neutropenic Enterocolitis During Endocrine Therapy With Abemaciclib for Metastatic Breast Cancer. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379793
- Age, Age-Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation-Wide Retrospective Cohort Study. Pharmacoepidemiology and drug safety · 16 Jun 2026 PMID 42301003
Preclinical: animal, cell and lab studies (4)
- Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma. Journal of biomedical science · 12 Nov 2026 PMID 43021317
- Integrated "gut-liver"-on-a-chip (iGLoC): an immune-competent and metabolically active microphysiological model of the gut-liver axis for drug screening, validated by abemaciclib pharmacokinetics, hepatotoxicity, and drug-drug interaction studies. Lab on a chip · 6 Aug 2026 PMID 42557890
- Therapy-associated lineage plasticity in DIPG following combined CDK4/6 inhibitor, temozolomide, and radiation. Cancer letters · 30 Jul 2026 PMID 42532370
- Development of a stability-indicating RP-UPLC method for simultaneous determination of Abemaciclib and Olaparib with LC-MS characterization of degradation products and in vitro performance evaluation. Journal of chromatographic science · 23 Jul 2026 PMID 42490602
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-07-24. Last written: 2026-09-04 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.